IL17A and pancreatic neoplasm: Some evidence has demonstrated that combining anti-IL-17A antibodies with gemcitabine represents an effective approach to enhancing the antitumor response by modulating macrophages, particularly in pancreatic cancer, for which gemcitabine is currently the most widely used anticancer drug [15].